GSK looks past Paxil
Executive Summary
GlaxoSmithKline assumes worldwide development and commercialization rights to Merck KGaA's Phase II antidepressant EMD 68843 under licensing agreement announced Feb. 15. EMD 68843 (SB 6579746-A) is a combined selective serotonin reuptake inhibitor/5HT-1a partial agonist